Stay updated with breaking news from Violetta refolo. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
ATH434 protects brain cells and improves motor function in Parkinsonian disorder Oral presentation at the American Academy of Neurology News provided by Share this article MELBOURNE, Australia , April 21, 2021 /PRNewswire/ Alterity Therapeutics (ASX: ATH,NASDAQ: ATHE) ( Alterity or the Company ) today announced an oral presentation of expanded animal data to support the commercialisation of its lead compound ATH434 in clinical development for the treatment of Parkinsonian disorders, at the American Academy of Neurology (AAN) virtual annual meeting. The AAN conference, held this week, is the world s preeminent clinical and scientific conference in the neurology space. The presentation titled ATH434 Preserves Dopaminergic Neurons, Reduces α-synuclein Oligomerization, and Improves Motor Function in a Transgenic Murine Multiple System Atrophy Model ....